These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 21325169)
1. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Van Roosbroeck K; Cox L; Tousseyn T; Lahortiga I; Gielen O; Cauwelier B; De Paepe P; Verhoef G; Marynen P; Vandenberghe P; De Wolf-Peeters C; Cools J; Wlodarska I Blood; 2011 Apr; 117(15):4056-64. PubMed ID: 21325169 [TBL] [Abstract][Full Text] [Related]
2. Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia. Downes CEJ; Rehn J; Heatley SL; Yeung D; McClure BJ; White DL Br J Haematol; 2022 Feb; 196(3):700-705. PubMed ID: 34697799 [TBL] [Abstract][Full Text] [Related]
3. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Fitzpatrick MJ; Massoth LR; Marcus C; Vergilio JA; Severson E; Duncan D; Ramkissoon SH; Hasserjian RP; Kim AS; Sohani AR; Williams EA; Nardi V Am J Surg Pathol; 2021 Jul; 45(7):895-904. PubMed ID: 34105517 [TBL] [Abstract][Full Text] [Related]
4. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Van Roosbroeck K; Cools J; Dierickx D; Thomas J; Vandenberghe P; Stul M; Delabie J; De Wolf-Peeters C; Marynen P; Wlodarska I Haematologica; 2010 Mar; 95(3):509-13. PubMed ID: 20207848 [TBL] [Abstract][Full Text] [Related]
5. SEC31A-ALK Fusion Gene in Lung Adenocarcinoma. Kim RN; Choi YL; Lee MS; Lira ME; Mao M; Mann D; Stahl J; Licon A; Choi SJ; Van Vrancken M; Han J; Wlodarska I; Kim J Cancer Res Treat; 2016 Jan; 48(1):398-402. PubMed ID: 25715771 [TBL] [Abstract][Full Text] [Related]
6. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Poitras JL; Dal Cin P; Aster JC; Deangelo DJ; Morton CC Genes Chromosomes Cancer; 2008 Oct; 47(10):884-9. PubMed ID: 18618714 [TBL] [Abstract][Full Text] [Related]
7. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Tirado CA; Chen W; Huang LJ; Laborde C; Hiemenz MC; Valdez F; Ho K; Winick N; Lou Z; Koduru P Leuk Res; 2010 Dec; 34(12):1674-6. PubMed ID: 20594592 [TBL] [Abstract][Full Text] [Related]
8. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways. Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194 [TBL] [Abstract][Full Text] [Related]
9. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Bain BJ; Ahmad S Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195 [TBL] [Abstract][Full Text] [Related]
10. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402 [TBL] [Abstract][Full Text] [Related]
12. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263 [TBL] [Abstract][Full Text] [Related]
13. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948 [TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature. Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723 [TBL] [Abstract][Full Text] [Related]
16. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753 [TBL] [Abstract][Full Text] [Related]
17. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519 [TBL] [Abstract][Full Text] [Related]
18. TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition. Lazarevic V; Lilljebjörn H; Olsson-Arvidsson L; Orsmark-Pietras C; Ågerstam H Genes Chromosomes Cancer; 2024 Aug; 63(8):e23261. PubMed ID: 39105620 [TBL] [Abstract][Full Text] [Related]
19. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074 [TBL] [Abstract][Full Text] [Related]